image credit- shutterstock
Life Biosciences, a US-based biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of ageing, has announced the signing of a Memorandum of Understanding (MoU) with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS), a joint research institute under the auspices of the SingHealth Duke-NUS Academic Medical Centre, to continue to build out its therapeutic portfolio.
The REMEDIS collaboration will enhance Life Bio’s growing R&D efforts to advance its cellular rejuvenation technology across age-related diseases by targeting multiple organ systems and will also continue to accelerate scientific capabilities in Singapore.
“Singapore is emerging as a global leader in healthy ageing with its renowned scientific talent and facilities. Our collaboration reflects our shared commitment to advancing transformative therapies that target the fundamental causes of aging,” said Jerry McLaughlin, Chief Executive Officer of Life Bio. “By combining REMEDIS’s biological and translational expertise with our Partial Epigenetic Reprogramming Platform, we have a powerful opportunity to accelerate development of novel therapeutics to reverse and prevent a wide range of age-related diseases. This partnership marks the first milestone in Life Bio’s strategy to align with leading research centres in longevity science across the globe.”
